风湿病学中的新疗法
Alison Bays1, Gregory C Gardner1
1Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA.
The Medical clinics of North America
|July 31, 2024
概括
新的风湿病药物,包括生物药物,针对特定的免疫系统组件. 这些先进疗法显示出比安慰剂和一些现有治疗方法更高的疗效,尽管感染风险需要仔细监测.
科学领域:
- 免疫学和风湿病学
- 免疫介导疾病的药理学进展
背景情况:
- 风湿病涉及复杂的免疫系统失调.
- 持续需要更有效,更有针对性的疗法.
研究的目的:
- 审查最近批准的和即将推出的类风湿病的药物.
- 突出针对性免疫疗法和小分子的进步.
主要方法:
- 审查最近的监管批准和管道药物在风湿病学.
- 对临床试验数据的分析,将新药与安慰剂和现有疗法进行比较.
主要成果:
- 讨论了11种新的药物,其中7种是生物制剂.
- 这些新型疗法显示出显著的疗效,表现优于安慰剂.
- 对比显示优于一些已建立的治疗方法,感染是主要的安全问题.
结论:
- 新的生物制剂和向分子代表了风湿病学的重大进展.
- 这些疗法通过精确调节免疫系统,提供了改进的治疗选择.
- 由于免疫调节效应,仔细管理感染风险至关重要.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:28Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
01:29Autoimmune Disorders
404
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
404
01:24T Cell Types and Functions
967
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
967
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413